Perceptive reports 8.4% stake in SAB Biotherapeutics
SAB Biotherapeutics reports a 5/12/2026 ownership disclosure by Perceptive Advisors and affiliated entities.
Rhea-AI Filing Summary
SAB Biotherapeutics reports a 5/12/2026 ownership disclosure by Perceptive Advisors and affiliated entities. The filing states that Perceptive Life Sciences Master Fund, Perceptive Advisors LLC and Joseph Edelman each may be deemed to beneficially own 6,431,743 shares of Common Stock, representing 8.4% of the class based on 76,464,094 shares outstanding as reported in the issuer's Form 10-Q filed on 5/12/2026.
The Master Fund directly holds 6,431,743 shares; Perceptive Advisors is the Master Fund's investment manager and Mr. Edelman is the managing member of Perceptive Advisors, each reported with shared voting and dispositive power over those shares.
Positive
- None.
Negative
- None.
Insights
Large passive stake disclosed; filing signals institutional influence but not control.
The Schedule 13G/A lists a 6,431,743-share position held directly by the Master Fund and attributed to Perceptive Advisors and Joseph Edelman as manager. The filing shows shared voting and dispositive power, not sole control.
Key dependencies include any subsequent amendments or conversion of this disclosure to a Schedule 13D if intent or control changes; timing for further disclosures would follow regulatory triggers.
Position equals 8.4% of the outstanding shares; material as an ownership disclosure only.
The ownership percent is calculated from 76,464,094 shares outstanding reported in the issuer's Form 10-Q dated 5/12/2026. The Master Fund is the direct holder; manager attribution is disclosed by agency relationship.
Cash‑flow treatment is not stated; market impact will depend on any future Schedule 13D amendment or open‑market trading disclosed in subsequent filings.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficially own regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Perceptive Advisors report in SABS?
Will this Schedule 13G/A trigger further disclosures about Perceptive's intentions for SABS?
AI-generated analysis. How Rhea-AI works. Not financial advice.